Comparing the Protective Effects of Two Cardioplegic Solutions, on Cardiac Metabolism, as Assessed Using Microdialysis
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
An estimated 8% to 15% of patients hospitalized for a coronary pathology undergo coronary
revascularization surgery with extracorporeal circulation (ECC). (1) Like most major cardiac
surgical interventions, it is performed with the heart stopped; this leads to more or less
severe myocardial ischemia. The heart is stopped (and therefore deprived of oxygen) for a
duration that varies depending on the number of bypasses required, and on the local
difficulties encountered. On average, myocardial ischemia lasts between 20 and 80 minutes.
Heart protection during coronary revascularization surgery remains a crucial factor in
limiting the heart's aerobic function during aortic clamping, and in minimizing the resulting
post-operatory ventricular dysfunction. Its quality is a determining factor of the
post-operatory issue.
High-performance heart protection solutions such as Custodiol have been used by heart
surgeons for a few years. They are used as an alternative choice to other cardioplegic
solutions, the efficacy of which has already been proven (St Thomas). These two myocardial
protection solutions have never been evaluated in an in vivo, randomized, comparative trial.